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Background: PROACTIVE is a psycho-educational support intervention for prostate cancer 
patients managed on Active Surveillance. PROACTIVE is comprised of two interdependent 
components: group workshops and internet delivered information modules. We conducted a 
feasibility study to determine the practicality of delivering PROACTIVE at two prostate cancer 
centres. 
 
Methods: The feasibility study was a mixed methods randomized parallel-group exploratory 
trial. Participants were randomised using a ratio of 3:1 PROACTIVE group to treatment as 
usual. Qualitative semi-structured interviews and quantitative measures were completed at 
baseline, intervention completion (week 6), and at 6-months follow-up. Interview transcripts 
were analysed thematically using Framework analysis. Descriptive statistics were used to 
examine recruitment and retention rates, and changing trends in outcome measures.  
 
Results: Most aspects of the research design and PROACTIVE intervention were acceptable to 
those participating in the study. In particular participants valued the opportunity to share and 
discuss experiences with other prostate cancer patients on Active Surveillance, and receive 
detailed authoritative information. However, three issues were identified:  
1. a low response rate (13 participants recruited, response rate 16%) 
2. low utilisation of internet delivered information modules 
3. self-perceived low levels of anxiety amongst participants with the majority perceiving 
their cancer as not impacting on their day-to-day life or causing anxiety.  
 
Conclusions: Due to these significant research design issues it is not recommended 
PROACTIVE be evaluated in a large scale randomised controlled trial. Further research is 
required to explore the impact of Active Surveillance on anxiety amongst men with localized 
prostate cancer managed by Active Surveillance. 
 





















Whilst prostate cancer is the commonest cancer in men, and the second commonest cause of 
cancer death in men, survival after a prostate cancer diagnosis has improved markedly over 
the last 15 years, in part due to diagnosis at an earlier stage. Men who are diagnosed with 
low-risk prostate cancer are advised to undergo active surveillance (AS). The cancer can be 
monitored, and if signs of more aggressive disease are seen then curative treatment can be 
offered at that point. This approach has been developed because prostate cancer treatment 
can be associated with significant side effects, such as urine leakage, bowel problems and 
difficulties with sexual function.1 AS involves deferring or avoiding unnecessary treatments, 
and instead, introducing surveillance for evidence of disease progression with biopsies, blood 
tests and, ideally, magnetic resonance imaging (MRI).2 A number of international 
organizations have updated their guidelines to include AS as a management strategy for low-
risk prostate cancer (prostate specific antigen <10ng/ml and Gleason score ≤6 and Clinical stage T1 
to T2a).2-5  
 
Previous studies have found varying levels of anxiety amongst prostate cancer patients 
managed with AS, ranging from 13% to 45%.6 A qualitative study involving men on AS revealed 
two over-arching themes: problems living with AS, and the supportive care requirements of 
AS patients.7 Anxiety is the most accurate predictor of low risk AS patients asking to access 
radical treatment without obvious clinical benefit.8,9 Men receiving radical treatment may 
experience significant physical consequences with no increase in survival. Therefore tailored 
support interventions that enable low risk AS patients to manage anxiety are warranted. Such 
interventions, with the aim of supporting patients through a better understanding of the 
processes involved in AS and why it represents the preferred treatment approach, are 
hypothesized to offer an effective means of managing anxiety.  
 
Previously published qualitative data7 were used to develop the PROACTIVE intervention 
(PROACTIVE: PROstate cancer support intervention for ACTIVE surveillance). The present 
study explores the feasibility of delivering PROACTIVE in a two centre feasibility study.  
 
Methods 
The study employed a mixed methods randomized parallel-group exploratory study design to 
determine the feasibility of delivering PROACTIVE within an NHS setting. This included 
preliminary data on the size of any effect and explored the views of patients about trial design 
and, for those allocated to the PROACTIVE intervention, their views on the intervention. 
Patients were recruited from the urology departments at University Hospital Southampton 
NHS Foundation Trust (UHS) and University College London Hospitals NHS Foundation Trust 
(UCLH).  
 
Inclusion criteria were as follows: 
• Low or intermediate risk prostate cancer as per NICE 2014 definition2 
• Access to the internet 
• Willing to participate and provide informed consent 
• Managed by AS for less than 12 months 
• No follow-up MRI subsequent to placement on AS 
• Fluent English (written and oral) 
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• No additional cancers (including non-melanomas) 
• No significant mental illness (such as psychosis) 
 
Participants were randomized to receive either PROACTIVE or Treatment as Usual (TAU) via 
the LifeGuide Website.10 Participants were randomised using a ratio of 3:1 intervention group 
to control group. Those allocated to TAU were provided with access to the PROACTIVE 
support website upon study completion. 
 
This investigation ran for 6 months with quantitative measures completed at baseline, 
intervention completion (week 6), and at 6 months follow-up. Questionnaires were 
completed electronically via the LifeGuide website with participants prompted to do so via 
email reminders. Patients were also asked to participate in semi-structured interviews at the 
same 3 time points. Telephone interviews lasting 20-70 minutes were conducted by an 
experienced qualitative interviewer, audio-recorded and transcribed verbatim. 
  




The study employed three validated outcome measures to determine their suitability to 
capture outcomes of interest in any future trial. The Hospital Anxiety and Depression Scale 
(HADS);11 The Warwickshire/Edinburgh Mental Wellbeing Scale (WEMWBS);12 and the 
Memorial Anxiety Scale for Prostate Cancer (MAX-PC).13 A Patient Demographics 
Questionnaire was also used to collect relevant demographic data. 
 
PROACTIVE Intervention 
PROACTIVE is a psycho-educational support intervention comprised of 2 individual 
interdependent components, group workshops and internet modules. 
 
Group Workshops 
PROACTIVE involved three 2-hour group workshops facilitated by two experienced Clinical 
Nurse Specialists. Each workshop addressed a different topic area, consisting of: 
 
• Workshop 1: Introduction and overview of AS (workshop provided participants with a 
detailed overview of the clinical rationale for AS and what being managed with AS 
involves whilst providing opportunity for group-based discussions about AS) 
• Workshop 2: Living and Feeling Well (workshop looked at the issues associated with 
stress and anxiety and introduced participants to two simple to use and easy to learn 
breathing based relaxation techniques) 
• Workshop 3: Wives and Partners Workshop (workshop introduced 
wives/partners/significant others of participants to PROACTIVE). 
 
Internet Modules 
PROACTIVE involved 6 weekly modules accessed through the web-based LifeGuide platform 
developed with the aim of complementing and extending information provided during 
workshops. Participants’ had access to all internet modules from the start of participation. 
Each internet module addressed a different component: 
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• Week 1 Module:  Information session about AS, physical activity advice 
• Week 2 Module:  Foods to eat, and an introduction to stress 
• Week 3 Module:  Relaxation and resilience techniques 
• Week 4 Module:  Talking to others 
• Week 5 Module:  Thoughts and feelings 




Descriptive statistics and graphical representations of quantitative data were used to examine 
recruitment and retention rates over the intervention; and changing trends in and between 
outcome measures.  
 
Qualitative data 
Interview transcripts were analysed thematically using Framework analysis.14,15 Framework 
Analysis is a manual, matrix method which facilitates thematic and cross-case interpretation. 
Interviews at each of the three time points addressed specific feasibility aims. All qualitative 
data were analysed together following study completion. 
 
Recruitment and Sample 
Patient screening and recruitment were conducted by clinical teams at both sites. Eligible 
patients were provided with a Patient Information Pack. Participants provided written 
consent via the LifeGuide website. For this feasibility study we sought to recruit 60 AS patients 
(30 per site). For a feasibility study of this nature, 60 participants was judged sufficient to 
allow us to answer the aims of the study. 
 
Results 
As a feasibility study, our outcomes were feasibility driven rather than hypothesis driven. 
Findings are presented according to the specific aims of the feasibility study:  
 
• recruitment processes and resources 
• intervention management and procedures 
• suitability of outcome measures. 
 
Recruitment Processes and Resources 
Recruitment took place between December 2015 and October 2016. 128 patients were 
screened for inclusion in the study (89 UHS, 39 UCLH). 48 were excluded as they did not fulfil 
inclusion criteria. 13 patients agreed and consented to take part in the study (6 UHS, 7 UCLH), 
representing an overall response rate of 16%. Of these, 10 were randomised to receive the 
PROACTIVE intervention and 3 TAU (see figure 1). Participant demographics can be seen in 
table 1.  
 
Thirty patients who declined to participate indicated their reasons for non-participation when 
they returned their decline slip, 12 were working and could not get time off to participate, 8 
said they were too busy, 6 saw no need in participating as they were happy with their AS 
management, and 4 were carers for family members.  
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All participants completed baseline assessments, 10 (77%) completed post-intervention 
questionnaires (7 intervention, 3 TAU), and 3 (23%) completed 6 month follow up 
questionnaires (2 intervention, 1 TAU).  
 
Anxiety and living with AS: With regards to qualitative interviews, 12 participants completed 
their pre-intervention interview (9 intervention, 3 TAU); 9 completed post-intervention 
interviews (6 intervention, 3 TAU); and 9 completed 6 month follow-up interviews (7 
intervention, 2 TAU).  
 
When asked during interviews about anxiety related to their prostate cancer all participants 
indicated they experienced increased levels of anxiety during the period whilst undergoing 
medical procedures leading to their cancer diagnosis. However, when receiving their 
diagnosis, almost all were reassured by their treating consultant that their prostate cancer 
was not severe and unlikely to cause them problems in the future. In the majority of cases 
participants did not perceive their cancer as impacting on their day-to-day life, and felt little 
cause for anxiety. Typically, the only time participants indicated they experienced any anxiety 
due to their cancer was when they were undergoing periodic assessments to monitor the 
progress of their condition (see quotations 1 and 2 in Table 2).  
 
Motivation for taking part and perceived ineligibility for the intervention: Participants’ 
primary motivation for taking part in the study was a desire to ‘give something back.’ Few 
participants were motivated by a desire for personal benefit. Indeed, due to participants’ 
perception of their cancer as non-severe, some felt their inclusion was unwarranted, with 
some referring to feeling like a ‘fraud’ or ‘imposter’ as they didn’t feel their condition justified 
intervention (see quotation 3 in Table 2).  
 
Views on randomisation: No participants expressed concerns relating to the randomisation 
process. Only one of the three participants allocated to TAU expressed disappointment at not 
receiving the PROACTIVE intervention.  
 
Intervention Management and Procedures 
No issues were identified relating to the feasibility and acceptability of the trial procedures. 
Those allocated to the PROACTIVE intervention experienced no difficulties attending 
workshops, and only one participant failed to attend all their workshop sessions. Participants 
were happy with the group format of the workshops, and felt comfortable discussing their 
experiences within the group.  
 
The size of the groups (containing 4 to 6 participants) was considered optimal, allowing 
participants an adequate opportunity to speak about their own experiences. Participants felt 
the number of workshops conducted, as well as the length of each workshop, was acceptable. 
Almost all participants were complimentary of the quality of the group sessions.  
 
Facilitators leading the sessions at both study sites were perceived as ‘skilful’ and 
‘knowledgeable.’ The sessions themselves being perceived as ‘informal and informative’, with 
subject matter well explained by facilitators. The level of detail included in the sessions was 
also perceived as ‘just right’, being neither too complex nor too simple.  
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Group workshops: Participants were encouraged during workshops to set lifestyle goals to 
improve their health and limit anxiety. However, qualitative interviews revealed many 
participants did not set any personal goals. Some said that they ‘don’t like setting goals’, while 
others did not see adjustments to their lifestyle as necessary due to AS not causing anxiety 
and/or being unlikely to impact on the development of their cancer.  
 
No participant had utilised the taught breathing techniques for anxiety related to their cancer, 
as none felt their condition had raised their anxiety levels sufficiently to warrant utilisation. 
However, some participants had used the breathing exercises for non-cancer related reasons 
and found them beneficial, and others felt they would utilise the breathing techniques should 
circumstances warrant in the future (see quotation 4 in Table 2).  
 
Online modules: Adherence to the online PROACTIVE modules was lower than for workshops, 
with a number of participants indicating during interviews that they did not access the web 
resource at all. Those who had accessed the website tended to do so only during the period 
of attending workshops to read around the topics covered during the workshops.  
 
The main reason for not accessing the website was that participants perceived their condition 
as not severe, with some indicating they would access the resource if their cancer progressed. 
Other factors affecting adherence to the website included a lack of available time and low 
usage of the internet generally. 
 
Although a number of participants had not utilised the website, it was considered an 
acceptable intervention. It was typically viewed by participants as an adjunct to the 
workshops, the latter perceived as the essential component of the PROACTIVE intervention. 
Those who did access the website indicated no problems navigating the website, with 
language and content perceived to be at an appropriate level (see quotation 5 in Table 2). 
 
Perceptions of the impact of the intervention: Some participants made lifestyle changes such 
as increased exercise or reduced alcohol consumption following the PROACTIVE intervention. 
However, participants were almost universally in agreement that involvement with the 
PROACTIVE intervention had not led to any significant changes to their day-to-day life or 
anxiety levels. Participants did however, perceive they derived benefit from the PROACTIVE 
intervention. In particular participants valued being able to share experiences with other 
prostate cancer patients ‘in the same boat’ as themselves. Participants typically felt reassured 
by listening and talking with other prostate cancer patients on AS.  
 
A number of participants also received contradictory advice and recommendations during 
their NHS care, and were additionally found to value the opportunity to receive accurate 
definitive information from an expert in prostate cancer care.  Participants often described 
feeling better informed around prostate cancer and AS as a result of receiving the PROACTIVE 
intervention. This led to participants feeling more secure in their decision to choose AS as a 
treatment option, and reassured about their continued future on AS (see quotations 6 and 7 
in Table 2).  
 
Suitability of Outcome Measures 
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All participants described the completion of study questionnaires as acceptable. Participants 
also indicated none of the questionnaires contained items deemed intrusive or sensitive in 
nature. However, some participants indicated they felt some questions were irrelevant to 
them, and would only relate to patients with a more severe illness (see quotation 8 in Table 
2).  
 
Despite participants qualitatively reporting a lack of anxiety, HADS scores at baseline indicate 
clinical levels of anxiety in all participants, and clinical levels of depression in 8 (61.5%) 
participants. All outcome measure scores remained largely stable for participants post-
intervention (see table 3) and at 6 month follow-up (see table 4).
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Discussion 
Although most aspects of the research design and PROACTIVE intervention were acceptable 
to those participating in the study, three major problems were identified:  
 
• recruitment of sufficient numbers 
• low utilisation of internet modules 
• self-perceived low levels of anxiety 
 
The study identified 80 eligible participants, but just 13 patients (16%) agreed to participate. 
Although the majority of those declining to participate cited work/time constraints for non-
participation, interviews with participants indicated they did not consider themselves to be 
suffering from undue anxiety related to their cancer diagnosis and AS monitoring. The present 
study found lower levels of self perceived anxiety than previously published research.6 It is 
noteworthy that many participants in the present study indicated that they had felt reassured 
by their treating consultant that their cancer was not severe and unlikely to cause them 
problems in the future. It is possible that greater confidence in AS as a treatment strategy by 
consultants has had a positive impact on prostate cancer patients’ levels of anxiety. However, 
further research is required to explore this further. 
 
Qualitative data indicated participants felt the PROACTIVE intervention had not impacted on 
their perceived anxiety levels, and quantitative data also indicated no trends towards any 
clinically meaningful differences between those treated with TAU and PROACTIVE. 
Interestingly, whilst quantitative data suggested all participants were experiencing clinically 
significant levels of anxiety, qualitative data revealed participants did not feel they were 
experiencing raised anxiety. Previous research has found problems in accurately screening 
cancer patients for clinical anxiety using the HADS anxiety subscale.16 Given the conflicting 
levels of prevalence of anxiety detected amongst prostate cancer patients managed on AS 
(previous studies found levels ranging from 13% to 45%)6 it is recommended further research 
be conducted to accurately assess levels of anxiety amongst AS prostate cancer patients 
longitudinally, and explore reasons for discrepancies between screening scales and patients’ 
perceived experience. 
 
One of the aims of the PROACTIVE intervention was to support AS patients with a better 
understanding of the processes involved in AS and why it represents the preferred treatment 
approach. Participants indicated during qualitative interviews they felt better informed about 
prostate cancer and AS as a result of receiving the PROACTIVE intervention, with many 
indicating they felt more secure in their decision to choose AS as a treatment option. Many 
participants also valued the peer support in the group workshop, a finding congruent with the 
findings of a recent qualitative synthesis of studies exploring prostate cancer patients’ 
experiences of supportive care provision.17 
 
To conclude, although participants were found to value the opportunity to share and discuss 
experiences with other prostate cancer patients on AS, and receive detailed authoritive 
information on AS, the study encountered significant issues with recruitment, utilisation of 
online modules, and participant anxiety levels. Although it is not advisable to conduct further 
research into PROACTIVE in its current format, further research is required to explore more 
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Table 2: Examples of participant quotes from qualitative interviews (participants identified by ACT 
(from proACTive) followed by participant number)  
 
Anxiety and living with AS 
1. ‘Well he[consultant] was very reassuring and fairly dismissive of it, so we didn’t think too much about 
it… he’d said that he hadn’t been able to find anything more serious, so basically he said – well it’s good 
















































Table 3: Within group comparison: scores at baseline and post intervention 
Outcome measure Mean at baseline Mean at follow-up Difference (95% CI) 
TAU    
 14 
HADS Anxiety 12.67 (SD=0.58) 14.67 (SD=0.58) 2.00 (-0.48, 4.48) 
HADS Depression 7.67 (SD=0.58) 7.67 (SD=1.15) 0.00 (-2.48, 2.48) 
HADS Total 20.33 (SD=0.58) 22.33 (SD=1.53) 2.00 (-2.30, 6.30) 
MAX-PC 17.67 (SD=3.06) 13.67 (SD=4.04) -4.00 (-10.57, 2.57) 
WEMWBS 60.00 (SD=6.25) 58.33 (SD=4.73) -1.67 (-20.50, 17.14) 
Intervention    
HADS Anxiety 13.22 (SD=1.99) 13.29 (SD=1.50) 0.14 (-0.85, 1.13) 
HADS Depression 8.67 (SD=1.73) 8.86 (SD=1.34) 0.14 (-0.65, 1.13) 
HADS Total 21.89 (SD=2.03) 22.14 (SD=1.57) 0.29 (-0.74, 1.32) 
MAX-PC 17.44 (SD=6.69) 18.43 (SD=5.26) 1.86 (-1.58, 5.29) 






















































Outcome measure   TAU Intervention 
(mean/SD) 
HADS Anxiety 13 13.5 (0.71)  
HADS Depression 9 9 (1.41)  
HADS Total 22  22.50 (0.71)  
MAX-PC 19  17 (1.41) 
WEMWBS 61 53.00 ( 15.56) 
